Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has become a popular method for determining the stage of a patient’s prostate cancer. However, researchers have identified a major pitfall in this imaging technique and are cautioning medical professionals to be aware of the potential for misdiagnosis when relying solely on PSMA PET. The study is featured in The Journal of Nuclear Medicine‘s September issue. {read more here}

The researchers identified 123 volunteers who both answered the earlier questions and had a PET scan with PiB an average of nearly 16 years later. They then analyzed this data to see if there was a correlation between participants who reported daytime sleepiness or napping and whether they scored positive for beta-amyloid deposition in their brains. {read more here}

Researchers have developed a new nuclear medicine imaging method that works by targeting cancer-associated fibroblasts (CAFs), sharing their findings in the Journal of Nuclear Medicine. The authors developed a PET tracer based on a FAP-specific enzyme inhibitor, which outperformed fluorodeoxyglucose and produced high-contrast images in animals and three actual patients.  {read more here}

“Patients with favorable results for both molecular response and interim PET had excellent outcomes,” the researchers wrote. “In contrast, the combination of a positive interim PET scan and no molecular response identified a group of patients at extremely high risk for treatment failure.” {read more here}